Patents by Inventor Daniel Plaksin

Daniel Plaksin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190358156
    Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network incorporating one or more pharmaceutically active ingredients, wherein the open matrix network comprises maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 11, 2018
    Publication date: November 28, 2019
    Applicant: Ferring B.V.
    Inventors: Ganeshchandra SONAVANE, Daniel PLAKSIN, Varinder AHUJA, Parag LOKHANDE, Devendra Kantilal JAIN
  • Patent number: 10464984
    Abstract: A host cell characterized in that it comprises integrated into its genome a sequence coding for the a chain of hCG, and use of the host cell to produce recombinant hCG.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 5, 2019
    Assignee: Ferring B.V.
    Inventors: Daniel Plaksin, Ayelet Grinhut
  • Publication number: 20180282396
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Application
    Filed: December 1, 2015
    Publication date: October 4, 2018
    Applicant: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Publication number: 20180079794
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: August 29, 2017
    Publication date: March 22, 2018
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20180030107
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: May 3, 2017
    Publication date: February 1, 2018
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 9771407
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: September 26, 2017
    Assignee: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 9757469
    Abstract: Polyethylene glycol modified human chorionic gonadotropin (hCG), preparations thereof, compositions thereof, and methods of preparation and use thereof are described.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: September 12, 2017
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jenny Aharanov
  • Patent number: 9676835
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: June 13, 2017
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 9546204
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 17, 2017
    Assignee: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20160347811
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: August 16, 2016
    Publication date: December 1, 2016
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 8975226
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: March 10, 2015
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20150065695
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: November 14, 2014
    Publication date: March 5, 2015
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 8951967
    Abstract: The present disclosure describes recombinant follicle stimulating hormone (FSH) and methods for the production thereof. The recombinant FSH can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant FSH can be produced in a human cell line such as a PER.C6® cell line.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: February 10, 2015
    Assignee: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20140249082
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 4, 2014
    Applicant: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20140088010
    Abstract: Preparations including poly (ethylene glycol) modified recombinant hCG(rhCG).
    Type: Application
    Filed: March 29, 2012
    Publication date: March 27, 2014
    Applicant: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jenny Aharanov
  • Publication number: 20130023476
    Abstract: Preparations including recombinant hCG (r hCG).
    Type: Application
    Filed: October 4, 2010
    Publication date: January 24, 2013
    Applicant: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20110105398
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: April 16, 2009
    Publication date: May 5, 2011
    Applicant: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20090220486
    Abstract: The present invention provides antibodies or fragments thereof that bind to cancer cells and is important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic methods and compositions using such antibody fragments thereof are also provided. The methods and compositions according to the present invention can be used in targeting therapeutic agents and in diagnosis, prognosis, and staging of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease. Also provided is a library of immunoglobulin binding domains having a diverse antigen-binding domain for complementary binding, wherein the library has diversity only in heavy chain CDR3.
    Type: Application
    Filed: January 8, 2008
    Publication date: September 3, 2009
    Inventors: Daniel Plaksin, Avigdor Levanon, Esther Szanton, Yocheved Hagay, Rachel Ben-Levy, Yael Nisgav, Yariv Kanfi
  • Publication number: 20070149768
    Abstract: The present invention is directed to a peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding selectivity or specificity is primarily determined by a first hypervariable region, and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags. The enhanced binding is directed to a substantially exposed and/or over-expressed binding site on or in a target comprising a cell in favor of other cells on or in which the binding site is not substantially available and/or expressed. The invention is further directed to a method for isolating such peptides and polypeptides from a phage display library and to the nucleic acid molecules encoding them.
    Type: Application
    Filed: March 22, 2006
    Publication date: June 28, 2007
    Inventors: Yocheved Hagay, Janette Lazarovits, Rachel Guy, Orly Lifshitz, Esther Szanton, Avigdor Levanon, Daniel Plaksin, Tuvia Peretz
  • Patent number: 7132510
    Abstract: The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having a heavy variable chain comprising CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOS:8, 115 and 114, respectively.
    Type: Grant
    Filed: December 31, 2001
    Date of Patent: November 7, 2006
    Assignee: Bio-Technology General (Israel) Ltd.
    Inventors: Yocheved Hagay, Janette Lazarovits, Rachel Guy, Orly Lifshitz, Esther Szanton, Avigdor Levanon, Daniel Plaksin, Tuvia Peretz